# Intrathecal Transplantation Of Autologous Adipose Tissue Derived MSC in the Patients With Spinal Cord Injury

> **NCT01624779** · PHASE1 · COMPLETED · sponsor: **Bukwang Pharmaceutical** · enrollment: 15 (estimated)

## Conditions studied

- Spinal Cord Injury

## Interventions

- **DRUG:** autologous adipose tissue derived mesenchymal stem cells

## Key facts

- **NCT ID:** NCT01624779
- **Lead sponsor:** Bukwang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2015-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01624779

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01624779, "Intrathecal Transplantation Of Autologous Adipose Tissue Derived MSC in the Patients With Spinal Cord Injury". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01624779. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*